High dose genistein in Sanfilippo syndrome: a randomised controlled trial

Abstract Infants born preterm miss out on the peak period of in utero DHA accretion to the brain during the last trimester of pregnancy which is hypothesised to contribute to the increased prevalence of neurodevelopmental deficits in this population. This study aimed to determine whether DHA supplementation in infants born preterm improves attention at 18 months’ corrected age. This is a follow-up of a subset of infants who participated in the N3RO randomised controlled trial. Infants were randomised to receive an enteral emulsion of high-dose DHA (60 mg/kg per d) or no DHA (soya oil – control) from within the first days of birth until 36 weeks’ post-menstrual age. The assessment of attention involved three tasks requiring the child to maintain attention on toy/s in either the presence or absence of competition or a distractor. The primary outcome was the child’s latency of distractibility when attention was focused on a toy. The primary outcome was available for seventy-three of the 120 infants that were eligible to participate. There was no evidence of a difference between groups in the latency of distractibility (adjusted mean difference: 0·08 s, 95 % CI –0·81, 0·97; P = 0·86). Enteral DHA supplementation did not result in improved attention in infants born preterm at 18 months’ corrected age.

Download Full-text

Prevention of oral mucositis in patients treated with high-dose chemotherapy and bone marrow transplantation: A randomised controlled trial comparing two protocols of dental care

European Journal of Cancer Part B Oral Oncology ◽

10.1016/0964-1955(94)90059-0 ◽

1994 ◽

Vol 30 (2) ◽

pp. 93-97 ◽

Cited By ~ 103

Author(s):

B. Borowski ◽

E. Benhamou ◽

J.L. Pico ◽

A. Laplanche ◽

J.P. Margainaud ◽

...

Keyword(s):

Bone Marrow ◽

Bone Marrow Transplantation ◽

Randomised Controlled Trial ◽

Oral Mucositis ◽

Dental Care ◽

Marrow Transplantation ◽

Controlled Trial ◽

High Dose Chemotherapy ◽

High Dose ◽

Randomised Controlled

Download Full-text

A randomised controlled trial of high-dose immunosuppression in paraquat poisoning

http://isrctn.org/> ◽

10.1186/isrctn85372848 ◽

2012 ◽

Author(s):

Pilane Liyanage Ariyananda

Keyword(s):

Randomised Controlled Trial ◽

Controlled Trial ◽

High Dose ◽

Paraquat Poisoning ◽

Randomised Controlled

Download Full-text

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial

The Lancet Infectious Diseases ◽

10.1016/s1473-3099(16)30274-2 ◽

2017 ◽

Vol 17 (1) ◽

pp. 39-49 ◽

Cited By ~ 157

Author(s):

Martin J Boeree ◽

Norbert Heinrich ◽

Rob Aarnoutse ◽

Andreas H Diacon ◽

Rodney Dawson ◽

...

Keyword(s):

Randomised Controlled Trial ◽

Controlled Trial ◽

High Dose ◽

Multi Stage ◽

Randomised Controlled

Download Full-text

Effect of adjunctive single high-dose vitamin D3 on outcome of community-acquired pneumonia in hospitalised adults: The VIDCAPS randomised controlled trial

Scientific Reports ◽

10.1038/s41598-018-32162-2 ◽

2018 ◽

Vol 8 (1) ◽

Cited By ~ 2

Author(s):

Sandy Slow ◽

◽

Michael Epton ◽

Malina Storer ◽

Rennae Thiessen ◽

...

Keyword(s):

Randomised Controlled Trial ◽

Vitamin D3 ◽

Controlled Trial ◽

Community Acquired Pneumonia ◽

High Dose ◽

Single High Dose ◽

Randomised Controlled ◽

High Dose Vitamin

Download Full-text

Randomised controlled trial for high-dose intravenous zinc as adjunctive therapy in SARS-CoV-2 (COVID-19) positive critically ill patients: trial protocol

BMJ Open ◽

10.1136/bmjopen-2020-040580 ◽

2020 ◽

Vol 10 (12) ◽

pp. e040580

Author(s):

Marlon Perera ◽

John El Khoury ◽

Vidyasagar Chinni ◽

Damien Bolton ◽

Liang Qu ◽

...

Keyword(s):

Randomised Controlled Trial ◽

Controlled Trial ◽

Respiratory Illness ◽

Organ Injury ◽

High Dose ◽

Protective Effects ◽

Double Blind ◽

Hospitalised Patients ◽

Randomised Controlled ◽

Ventilated Patients

IntroductionSARS-CoV-2 (COVID-19) has caused an international pandemic of respiratory illness, resulting in significant healthcare and economic turmoil. To date, no robust vaccine or treatment has been identified. Elemental zinc has previously been demonstrated to have beneficial effects on coronaviruses and other viral respiratory infections due to its effect on RNA polymerase. Additionally, zinc has well-demonstrated protective effects against hypoxic injury—a clear mechanism of end-organ injury in respiratory distress syndrome. We aimed to assess the effect of high-dose intravenous zinc (HDIVZn) on SARS-CoV-2 infection. The end of study analyses will evaluate the reduction of impact of oxygen saturations or requirement of oxygen supplementation.Methods and analysisWe designed a double-blind randomised controlled trial of daily HDIVZn (0.5 mg/kg) versus placebo. Primary outcome measures are lowest oxygen saturation (or greatest level of supplemental oxygenation) for non-ventilated patients and worst PaO2/FiO2 for ventilated patients. Following power calculations, 60 hospitalised patients and 100 ventilated patients will be recruited to demonstrate a 20% difference. The duration of follow-up is up to the point of discharge.Ethics and disseminationEthical approval was obtained through the independent Human Research Ethics Committee. Participant recruitment will commence in May 2020. Results will be published in peer-reviewed medical journals.Trial registration numberACTRN126200000454976.

Download Full-text